Becton, Dickinson and Company (NYSE:BDX) Stake Held by American National Insurance Co. TX

American National Insurance Co. TX maintained its position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, Holdings Channel reports. The firm owned 7,091 shares of the medical instruments supplier’s stock at the end of the second quarter. American National Insurance Co. TX’s holdings in Becton, Dickinson and were worth $1,384,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Chevy Chase Trust Holdings Inc. increased its position in Becton, Dickinson and by 1.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 257,374 shares of the medical instruments supplier’s stock worth $47,213,000 after buying an additional 4,083 shares during the period. Cohen Lawrence B increased its position in Becton, Dickinson and by 39.1% in the first quarter. Cohen Lawrence B now owns 4,272 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 1,200 shares during the period. Triangle Securities Wealth Management increased its position in Becton, Dickinson and by 0.6% in the first quarter. Triangle Securities Wealth Management now owns 3,896 shares of the medical instruments supplier’s stock worth $715,000 after buying an additional 25 shares during the period. Atalanta Sosnoff Capital LLC bought a new position in Becton, Dickinson and during the first quarter worth approximately $27,395,000. Finally, Private Asset Management Inc. bought a new position in Becton, Dickinson and during the first quarter worth approximately $956,000. 75.42% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (BDX) opened at 205.30 on Friday. The company has a market capitalization of $43.79 billion, a PE ratio of 34.10 and a beta of 1.05. The stock’s 50 day moving average price is $195.21 and its 200 day moving average price is $184.45. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $205.73.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.23 by $0.07. Becton, Dickinson and had a net margin of 10.67% and a return on equity of 25.37%. The firm had revenue of $2.97 billion for the quarter, compared to the consensus estimate of $2.92 billion. During the same quarter in the previous year, the firm posted $2.18 EPS. The firm’s quarterly revenue was down 3.2% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.45 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 9th were paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.42%. The ex-dividend date was Wednesday, June 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is 48.26%.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was first posted by [[site]] and is the property of of [[site]]. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at [[permalink]].

A number of research analysts recently commented on the company. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, July 17th. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Finally, Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their target price for the company from $210.00 to $180.00 in a research report on Friday, June 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $194.69.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).